ArticleThe oncologist2025

Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.

Anna Amela Valsecchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.